BioNTech Bilan de santé

Santé financière contrôle des critères 6/6

BioNTech possède un total de capitaux propres de €19.1B et une dette totale de €0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont €22.4B et de €3.3B.

Informations clés

Ratio d'endettement

€0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	€16.71b
Fonds propres	€19.11b
Total du passif	€3.29b
Total des actifs	€22.40b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de BNTX ( €18.5B ) dépassent ses passifs à court terme ( €2.5B ).

Passif à long terme: Les actifs à court terme de BNTX ( €18.5B ) dépassent ses passifs à long terme ( €764.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: BNTX est sans dette.

Réduire la dette: BNTX n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 3.3%.

Couverture de la dette: BNTX n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.

Couverture des intérêts: BNTX n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.

BioNTech Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023)

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

New major risk - Revenue and earnings growth

New major risk - Share price stability

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

New major risk - Revenue and earnings growth

New minor risk - Profit margin trend

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

New minor risk - Shareholder dilution

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022)

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

Investor sentiment deteriorates as stock falls 16%

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Second quarter 2023 earnings released: €0.79 loss per share (vs €6.86 profit in 2Q 2022)

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

New minor risk - Share price stability

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: €38.78 (vs €42.18 in FY 2021)

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Third quarter 2022 earnings released: EPS: €7.43 (vs €13.14 in 3Q 2021)

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union

Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO

Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months Through 4 Years of Age

Pfizer and Biontech Submits Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine

Analyse de la situation financière